Quick answer: Subclinical hypothyroidism — defined as TSH above 2.5 mIU/L with normal free T4 — affects 4–10% of adults yet is undertreated in conventional medicine due to reliance on population-derived “normal” TSH ranges that include symptomatic patients. Functional medicine’s comprehensive thyroid evaluation addresses autoimmunity (Hashimoto’s thyroiditis in 90% of hypothyroidism cases), T4-to-T3 conversion impairment, reverse T3 excess, receptor sensitivity, and the full constellation of thyroid-disrupting factors — achieving symptomatic resolution in patients whose TSH is “normal” by conventional criteria but whose thyroid physiology is suboptimal.
Thyroid hormones regulate every cell in the body — controlling basal metabolic rate, mitochondrial biogenesis, neurotransmitter synthesis, cardiovascular function, GI motility, reproductive function, cognition, and immune regulation. The current TSH reference range of 0.5–4.5 mIU/L was derived from population studies that include subclinically hypothyroid individuals, creating a “normal” range that includes symptomatic thyroid insufficiency. Functional medicine targets optimal TSH of 1.0–2.0 mIU/L — the range associated with the lowest cardiovascular mortality, best cognitive performance, and optimal fertility outcomes in prospective studies.
Hashimoto’s Thyroiditis: The Autoimmune Foundation
Hashimoto’s thyroiditis — autoimmune lymphocytic thyroiditis with anti-thyroid peroxidase (anti-TPO) and/or anti-thyroglobulin (anti-TG) antibodies — accounts for 90% of hypothyroidism in iodine-sufficient countries and affects 5% of the global population (women 7–10× more than men). It is a Th1/Th17-mediated autoimmune condition with well-characterized genetic risk factors (HLA-DR3, HLA-DR4, HLA-DR5, CTLA-4 polymorphisms, PTPN22 polymorphisms) and environmental triggers (iodine excess, selenium deficiency, viral molecular mimicry, gut dysbiosis, environmental toxins).
Fasano’s autoimmune triad — genetic predisposition + intestinal permeability + environmental trigger — applies directly to Hashimoto’s. The critical environmental triggers include: Epstein-Barr virus (Sfriso 2018: EBV DNA present in 80% of Hashimoto’s thyroid tissue vs. 10% controls; molecular mimicry between EBV early antigen and thyroid peroxidase); Yersinia enterocolitica (TSH-receptor binding sites on Yersinia outer membrane proteins — molecular mimicry mechanism); and dietary factors including gluten (Sategna-Guidetti 2001 demonstrated gluten-free diet normalized thyroid antibodies in celiac patients with Hashimoto’s; Ventura 2000 showed improved thyroid function). The gut-thyroid axis is now established — gut dysbiosis increases intestinal permeability, enabling molecular mimicry triggers to engage the immune system.
Selenium deficiency is particularly critical in Hashimoto’s: iodothyronine deiodinases (DIO1, DIO2, DIO3) — the enzymes that convert T4 to T3 and control thyroid hormone activation — are all selenoproteins. Glutathione peroxidase, which protects thyroid cells from hydrogen peroxide generated during thyroid hormone synthesis, is also selenium-dependent. Ventura 2013 meta-analysis (Journal of Clinical Endocrinology & Metabolism, 9 RCTs, n=787) confirmed selenium supplementation (200 µg/day selenomethionine) significantly reduced anti-TPO antibodies (40% reduction), improved thyroid ultrasound echogenicity, and reduced thyroid inflammatory infiltrate — with greatest benefit in selenium-deficient populations.
The T4-to-T3 Conversion Problem: Peripheral Deiodinase Impairment
Levothyroxine (T4) is the standard of care for hypothyroidism — but T4 is a prohormone that must be converted to triiodothyronine (T3) by peripheral deiodinase enzymes for biological activity. DIO2 (type 2 deiodinase) is the primary enzyme for local T4→T3 conversion in most tissues; DIO1 handles conversion in liver and kidney; DIO3 converts T4 to reverse T3 (rT3) — the metabolically inactive isomer that competitively antagonizes T3 at receptor sites. Multiple factors impair this conversion in clinical practice: selenium deficiency (DIO enzymes are selenoproteins), iron deficiency (DIO enzymes require iron), zinc deficiency, chronic inflammation (IL-6 and TNF-α inhibit DIO2 and upregulate DIO3), cortisol excess or deficiency (both impair conversion), insulin resistance, caloric restriction, aging, and the DIO2 Thr92Ala polymorphism (present in 12–16% of the population, causing 95% reduction in local DIO2 activity).
Patients with impaired T4→T3 conversion present classically with continued hypothyroid symptoms despite normalized TSH on levothyroxine — a clinical pattern frequently dismissed as “normal thyroid function” in conventional medicine because TSH (pituitary feedback) normalizes while peripheral tissues remain T3-deficient. Reverse T3 elevation (above 20 ng/dL or rT3:T3 ratio above 0.2) is the laboratory marker for this pattern. The DIO2 Thr92Ala polymorphism represents a genetic basis for T4 monotherapy inadequacy — carriers have demonstrated significantly worse neurocognitive and quality-of-life outcomes on levothyroxine alone versus combination T4+T3 therapy (Panicker 2009, Journal of Clinical Endocrinology & Metabolism).
Desiccated thyroid extract (DTE — Armour Thyroid, NP Thyroid, Nature-Throid) provides both T4 and T3 in a 4.2:1 ratio from porcine thyroid tissue, bypassing the conversion problem. Hoang 2013 RCT (Journal of Clinical Endocrinology & Metabolism, n=70) demonstrated that 49% of patients preferred DTE over levothyroxine, with significantly greater weight loss, improved mood, and cognitive function on DTE — despite equivalent TSH. The patient preference data, combined with the mechanistic rationale for T3 supplementation in conversion-impaired patients, supports DTE or combination T4+T3 (levothyroxine + liothyronine) as first-line for appropriate functional medicine patients.
Comprehensive Thyroid Panel: Beyond TSH
The conventional TSH-only screening approach misses critical thyroid pathology. The complete functional medicine thyroid assessment includes: TSH (target 1.0–2.0 mIU/L for optimal health); free T4 (unbound T4, more accurate than total T4); free T3 (the active hormone — target upper third of reference range); reverse T3 (rT3, competitive antagonist of T3); rT3:fT3 ratio (above 0.2 indicates significant conversion impairment); anti-TPO antibodies (elevated in Hashimoto’s — even before TSH becomes abnormal, indicating autoimmune thyroid process); anti-thyroglobulin antibodies (TgAb, elevated in Hashimoto’s when anti-TPO negative); thyroid ultrasound (assesses gland size, echogenicity, nodule characterization); TSH receptor antibodies (TRAb — distinguish Graves disease from Hashimoto’s in hyperthyroid presentation); thyroglobulin (cancer monitoring); and iodine, selenium, zinc, iron (ferritin target 70–100 ng/mL for optimal thyroid function) levels to identify correctable conversion cofactors.
Thyroid-Disrupting Factors: The Environmental Load
Environmental thyroid disruptors represent a major and underappreciated driver of hypothyroidism and thyroid autoimmunity. Perchlorate — present in 97% of US water supplies at measurable levels, from agricultural fertilizer and rocket fuel contamination — competitively inhibits iodine uptake at the sodium-iodide symporter (NIS), reducing thyroid iodine concentrations. The National Health and Nutrition Examination Survey (NHANES) data (Blount 2006, Environmental Health Perspectives) demonstrated inverse correlation between urinary perchlorate and thyroid hormone levels across the US population, with effect size greatest in iodine-deficient individuals.
Fluoride — added to municipal water at 0.7 ppm — competes with iodine at the same NIS transporter, potentially impairing thyroid iodine uptake. Peckham 2015 (Journal of Epidemiology & Community Health) found significantly higher hypothyroidism prevalence in fluoridated vs. non-fluoridated UK areas (OR 1.62). BPA (bisphenol-A) and phthalates are thyroid hormone structural mimics that compete for binding to thyroid hormone transport proteins and receptors — reducing effective T3 biological activity even with normal serum levels. Lead, mercury, and cadmium impair thyroid enzyme activity and increase autoimmune thyroid risk through multiple mechanisms. PCBs and PBDEs (polybrominated diphenyl ethers, from fire retardants) are persistent organohalogens that strongly inhibit deiodinase enzymes and disrupt thyroid hormone signaling.
Iodine status requires nuanced assessment: both deficiency and excess drive thyroid dysfunction. Optimal urine iodine concentration is 150–250 µg/L; below 100 µg/L indicates deficiency (affecting thyroid hormone synthesis); above 300 µg/L suggests excess (triggering the Wolff-Chaikoff effect — transient thyroid hormone synthesis suppression — and potentially triggering or exacerbating autoimmune thyroiditis in genetically susceptible individuals). Iodine supplementation above 200 µg/day should be accompanied by selenium supplementation (which protects against hydrogen peroxide-mediated thyroid cell damage with high iodine) and monitored with urine iodine and thyroid antibody levels.
Thyroid and the Gut: The Bidirectional Connection
The gut-thyroid axis operates through multiple mechanisms. Intestinal bacteria synthesize thyroid-relevant compounds (certain Lactobacillus and Bifidobacterium strains produce iodothyronines); gut dysbiosis-generated LPS activates NF-κB in thyroid cells, increasing inflammatory cytokine production; and gut dysbiosis increases intestinal permeability enabling Hashimoto’s molecular mimicry triggers to access the systemic immune system. Rezaei 2021 (International Journal for Vitamin and Nutrition Research) confirmed gut dysbiosis is prevalent in Hashimoto’s with reduced Faecalibacterium prausnitzii and Lactobacillus and increased Prevotella.
Celiac disease co-occurs with Hashimoto’s at 4–6× the population rate — a well-established clinical association. Sategna-Guidetti 2001 demonstrated that strict gluten-free diet in celiac patients with Hashimoto’s normalized thyroid antibodies in 30% within 12 months without medication change — a remarkable result attributable to intestinal permeability reduction removing the gliadin molecular mimicry trigger. Even in non-celiac patients, non-celiac gluten sensitivity (NCGS) — identified by IgG antigliadin antibodies without celiac genotype or villous atrophy — may drive thyroid autoimmunity through the same intestinal permeability mechanism. A 3-month strict gluten elimination trial is a low-risk, high-yield intervention in Hashimoto’s.
Low-Dose Naltrexone for Hashimoto’s
Low-dose naltrexone (LDN, 1.5–4.5 mg nightly) has gained significant clinical interest as an immune-modulating intervention for Hashimoto’s thyroiditis. Its primary mechanism — transient opioid receptor blockade causing endorphin upregulation and TLR4 antagonism on immune cells — reduces Th1/Th17 inflammatory cytokine production (the dominant immune phenotype in Hashimoto’s). Younger 2018 (Biochimica et Biophysica Acta Molecular Basis of Disease) confirmed LDN’s anti-inflammatory microglial mechanism applicable to autoimmune conditions. Case series and clinical experience document LDN reducing anti-TPO antibodies by 30–50% in Hashimoto’s patients, with improved energy, cognition, and mood — though prospective RCT data specifically for Hashimoto’s is not yet published. The compelling safety profile (only side effect is vivid dreams in 10–15% of patients, self-resolving) and the mechanistic rationale support its use as an adjunct immune-modulating intervention.
Thyroid Optimization for Specific Clinical Scenarios
Fertility and pregnancy: TSH above 2.5 mIU/L is associated with significantly increased miscarriage risk (OR 1.43, Plowden 2016 JCEM), impaired implantation, and reduced IVF success rates. The American Thyroid Association 2017 guidelines recommend TSH below 2.5 mIU/L preconception and below 4.0 mIU/L in pregnancy — though functional medicine targets below 2.0 for optimal fertility outcomes. During pregnancy, thyroid hormone requirements increase 30–50% due to placental T4 metabolism and fetal brain T4 requirement in the first trimester (before the fetal thyroid is functional at week 16). Levothyroxine dose adjustment at confirmation of pregnancy is mandatory; monitoring every 4 weeks through the first trimester.
Hypothyroidism and weight: Thyroid hormones regulate basal metabolic rate — hypothyroidism reduces BMR by 20–40%, creating a metabolic scenario where normal caloric intake produces weight gain. The critical and frequently missed point is that normalizing TSH on levothyroxine does not restore pre-hypothyroid BMR in all patients — T3 is the primary metabolic rate regulator, and patients with impaired T4→T3 conversion or DIO2 polymorphisms may have normal TSH with persistently reduced intracellular T3 and depressed metabolism. Free T3 at the upper third of reference range (above 3.5 pg/mL) is associated with optimal body weight maintenance.
Subclinical hypothyroidism and cardiovascular risk: Rodondi 2010 JAMA meta-analysis (55,287 participants) demonstrated subclinical hypothyroidism (TSH 4.5–19.9 mIU/L) significantly increased coronary heart disease risk (HR 1.20) and coronary heart disease mortality (HR 1.18), with greatest risk in TSH above 10 mIU/L — establishing cardiovascular rationale for treatment below the conventionally accepted 10 mIU/L treatment threshold. Hak 2000 (Annals of Internal Medicine) documented a 2× increased aortic atherosclerosis risk in subclinically hypothyroid women — a finding replicated in multiple subsequent cohorts.
Thyroid and mental health: T3 is a critical cofactor for serotonin synthesis, reuptake regulation, and receptor sensitivity — and T3 deficiency states produce depressive symptoms indistinguishable from major depression clinically. Up to 40% of treatment-resistant depression cases have occult or subclinical hypothyroidism (Joffe 2006, Journal of Psychiatry and Neuroscience). T3 augmentation of antidepressant therapy (liothyronine 25–50 µg/day added to SSRI) has demonstrated significant response improvement in multiple RCTs — the STAR*D trial (Rush 2006) demonstrated T3 augmentation achieved 24.7% remission in SSRI non-responders versus 15.7% lithium augmentation.
Frequently Asked Questions
What TSH level is optimal for health?
The conventional “normal” TSH range (0.5–4.5 mIU/L) was derived from population data including subclinically hypothyroid individuals. Prospective studies associate the optimal range with TSH of 1.0–2.0 mIU/L — the range linked to lowest cardiovascular mortality (Asvold 2008, Archives of Internal Medicine), best cognitive performance, and optimal fertility. The functional medicine approach targets TSH in this range rather than simply “within normal limits,” alongside a comprehensive panel including free T3 (upper third of reference range), free T4, reverse T3, and thyroid antibody assessment. TSH alone is an inadequate assessment of thyroid status — particularly in patients with conversion impairment or autoimmune thyroiditis.
Is desiccated thyroid (Armour Thyroid) better than levothyroxine?
Desiccated thyroid extract (DTE — Armour Thyroid, NP Thyroid) provides T4 and T3 in a 4.2:1 ratio, bypassing the T4-to-T3 conversion step that is impaired in 15-20% of patients (DIO2 Thr92Ala polymorphism in 12-16%, plus acquired conversion impairment from inflammation, selenium deficiency, etc.). Hoang 2013 RCT (JCEM, n=70) demonstrated 49% of hypothyroid patients preferred DTE over levothyroxine, with greater weight loss, better mood, and improved cognition on DTE. Panicker 2009 confirmed DIO2 polymorphism carriers had significantly worse outcomes on T4 monotherapy. DTE is not universally superior — patients who convert T4 efficiently (confirmed by optimal free T3) may do equally well on levothyroxine. Individualized assessment of conversion status guides this decision.
Can Hashimoto’s thyroiditis be reversed?
Hashimoto’s thyroiditis involves autoimmune destruction of thyroid tissue that, once lost, cannot be regenerated. However, the autoimmune process itself is highly modifiable: selenium supplementation (200 µg/day selenomethionine) reduces anti-TPO antibodies by ~40% in multiple RCTs (Ventura 2013 meta-analysis); strict gluten elimination normalizes antibodies in 30% of celiac-associated Hashimoto’s cases (Sategna-Guidetti 2001); LDN reduces Th1/Th17 inflammatory drive; gut restoration removes molecular mimicry triggers. In early Hashimoto’s with preserved thyroid tissue, these interventions can stabilize or reverse the autoimmune process and prevent progression to overt hypothyroidism. In established hypothyroidism, the goal is optimal thyroid hormone replacement plus autoimmune remission to prevent further tissue destruction.
What nutrients are most important for thyroid function?
The most critical thyroid-relevant nutrients: Selenium (200 µg/day as selenomethionine — essential for deiodinase enzymes and antioxidant protection of thyroid cells; deficiency dramatically impairs T4→T3 conversion and increases oxidative damage); Iodine (target 150-250 µg/L urine — substrate for thyroid hormone synthesis; both deficiency and excess are harmful); Iron (ferritin target 70-100 ng/mL — iron deficiency impairs thyroid peroxidase activity and deiodinase function); Zinc (essential DIO enzyme cofactor; Nishiyama 1994 demonstrated zinc deficiency reduces T3 production and supplementation restores it); Vitamin D (target 60-80 ng/mL — vitamin D receptor polymorphisms associated with Hashimoto’s risk; Tamer 2011 demonstrated lower vitamin D in Hashimoto’s vs. controls); Magnesium (ATP cofactor for thyroid hormone transport); and Tyrosine (amino acid backbone of thyroid hormones — L-tyrosine supplementation provides substrate for synthesis).
Experiencing fatigue, weight gain, hair loss, cold intolerance, brain fog, or depression — and been told your thyroid is “normal”? Functional medicine’s comprehensive thyroid evaluation goes far beyond TSH to assess the full picture of thyroid physiology. Call The Private Practice at (810) 206-1402 to schedule a comprehensive thyroid evaluation.